MaRS Innovation-backed Triphase to sell compound to Celgene
Triphase Accelerator Corp, a portfolio company of MaRS Innovation, has agreed to sell assets relating to its first investigational compound, marizomib, to Celgene Corp. No financial terms were disclosed. Triphase, a Toronto cancer-focused biotechnology accelerator, was launched by MaRS Innovation in partnership with the Ontario Institute for Cancer Research and MaRS Discovery District in January 2014. Celgene is a strategic partner. MaRS Innovation said the sale of marizomib, a novel brain-penetrant proteasome inhibitor used to treat glioblastoma, marks its first major portfolio exit.
21 November 2016•4 mins read
